Intestinal Research

Review

IBD

What to do when traditional rescue therapies fail in acute severe ulcerative colitis: Christopher F. D. Li Wai Suen, Matthew C. Choy, Peter De Cruz; Intest Res 2024;22(4):397-413. Published online May 16, 2024; DOI: https://doi.org/10.5217/ir.2024.00003

Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately 25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC are highly variable. Approximately 30% of patients do not respond to corticosteroids and up to 50% of patients do not respond to rescue therapy (infliximab or cyclosporin) and require emergency colectomy. Data are emerging on infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase inhibition as primary and sequential therapy. In this review, we outline contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.

Citations

Citations to this article as recorded by

Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
Christopher F.D. Li Wai Suen, Matthew C. Choy, Danny Con, Kaylene Cheng, Julie Nigro, Kerry Breheney, Kristy Boyd, Raquel Pena, Kathryn Burrell, Ourania Rosella, David Proud, Richard Brouwer, Alexandra Gorelik, Danny Liew, William R. Connell, Emily K. Wri
Gastroenterology.2026; 170(1): 118. CrossRef
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha
Intestinal Research.2026; 24(1): 27. CrossRef
Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department
Christopher F. D. Li Wai Suen, Shipraa Kaul, Ethan X. Z. Tan, Danny Con, Michelle Taylor, Joanne Wiid, Chris Hogan, Matthew C. Choy, Kumar Visvanathan, Peter De Cruz
Digestive Diseases and Sciences.2026;[Epub] CrossRef
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis – Authors’ reply
Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Peter De Cruz
The Lancet Gastroenterology & Hepatology.2025; 10(1): 19. CrossRef
Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review
Javier P Gisbert, María Chaparro
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series
Amirah Etchegaray, George Tambakis, Rina Kumar, Anthony Croft, Graham Radford-Smith, Gareth J. Walker
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Gut and Liver.2025; 19(3): 376. CrossRef
Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead?
Yoon Suk Jung
Intestinal Research.2025; 23(4): 394. CrossRef
Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
Javier P Gisbert, María Chaparro
Inflammatory Bowel Diseases.2025;[Epub] CrossRef
Recent Advances in the Management of Acute Severe Ulcerative Colitis
Elaine Ong Ming San, Kassem Sharif, Konstantina Rosiou, Michael Rennie, Christian Philipp Selinger
Journal of Clinical Medicine.2024; 13(23): 7446. CrossRef

11,617 View
387 Download
10 Web of Science
10 Crossref

First
Prev
Page of 1
Next
Last

Search